---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-331556"
form_type: "8-K"
ticker: "PVLA"
cik: "0001583648"
company_name: "PALVELLA THERAPEUTICS, INC."
filed_at: "2026-08-04T11:30:19+00:00"
generated_at: "2026-08-04T11:35:30.768774+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Palvella reports Q2 net loss $21.9M; submits first NDA module for QTORIN rapamycin

## Summary
- Net loss $21.9M ($1.52/share) vs $9.5M ($0.86) in Q2 2025; R&D spend $12.5M (up from $5.1M).
- Cash, equivalents, and short-term investments $250.6M as of June 30, 2026.
- Submitted first module of rolling NDA for QTORIN rapamycin in microcystic lymphatic malformations; completion on track for H2 2026.
- Planned U.S. commercial launch in H1 2027 if approved; Phase 3 trial for cutaneous venous malformations planned for Q4 2026.
- Appointed Matt Pauls to Board; uplisted to Nasdaq Global Market.

## SEC filing metadata
- accession: 0001193125-26-331556
- form_type: 8-K
- ticker: PVLA
- cik: 0001583648
- company_name: PALVELLA THERAPEUTICS, INC.
- filed_at: 2026-08-04T11:30:19+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583648/000119312526331556/0001193125-26-331556-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583648/000119312526331556/pvla-20260804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-331556
- JSON: https://secwatch.observer/filing/0001193125-26-331556.json
- Plain text: https://secwatch.observer/filing/0001193125-26-331556.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.